LENZ Therapeutics, Inc.

LENZ Healthcare Biotechnology

LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million. In the quarter to June 2026, revenue grew 9.72%, EPS fell 92.5% and free cash flow fell 229.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.27 0.30 −8.40%
Market cap
$112.2M
P/E
0.0×
Fwd P/E
−1.6×
Dividend yield
0.00%
F-score
n/a
Altman Z
11.98
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(28.78%) (33.63%) (49.71%) (59.21%)
ROA
(27.09%) (31.52%) (46.01%) (55.52%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(30.68%) (29.18%) (44.73%) (58.05%)
Average Days of Receivables
— 0.00 5.96 7.51
Free Cash Flow per Share
(1.62) (2.43) (2.79) (3.65)
Free Cash Flow
(46.16) (70.00) (87.44) (114.42)
Other line items

Show all line items

Columns are period end dates